Role of interleukin 6 in innate immunity to mycobacterium tuberculosis infection

Journal of Infectious Diseases

Volumn 207, Issue 8, 2013, Pages 1253-1261

  Martinez, Alejandra N ^a   Mehra, Smriti ^b   Kaushal, Deepak ^a,b  

^a Divisions of Bacteriology and Parasitology ^*  (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Il6; M. tuberculosis; macrophages; sigma factor; silencing

Indexed keywords

INTERFERON; INTERLEUKIN 6; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL ACTIVATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENETIC TRANSCRIPTION; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUBERCULOSIS;

ANIMALS; BACTERIAL LOAD; CHEMOKINE CXCL2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; IMMUNITY, INNATE; INFLAMMATION; INTERFERON TYPE I; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TOLL-LIKE RECEPTOR 2; TRANSCRIPTOME; TRANSFECTION; TUBERCULOSIS;

EID: 84875584821     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit037     Document Type: Article

References (44)

1. Ehrt S, Schnappinger D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol 2009; 11:1170-8.
2. Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 2007; 27:347-62.
3. Flannagan RS, Cosio G, Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009; 7:355-66.
4. Flynn JL, Chan J. Immune evasion by Mycobacterium tuberculosis: living with the enemy. Curr Opin Immunol 2003; 15:450-5.
5. Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010; 8:296-307.
6. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393-422.
7. Roy CR, Mocarski ES. Pathogen subversion of cell-intrinsic innate immunity. Nat. Immunol 2007; 8:1179-87.
8. Dutta NK, Mehra S, Martinez AN, et al. The stress-response factor SigH modulates the interaction between Mycobacterium tuberculosis and host phagocytes. PLoS One 2012; 7:e28958.
9. Sodenkamp J, Waetzig GH, Scheller J, et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 2012; 217: 996:1004.
10. Ladel CH, Blum C, Dreher A, Reifenberg K, Kopf M, Kaufmann SH. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun 1997; 65:4843.
11. Saunders BM, Frank AA, Orme IM, Cooper AM. Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 2000; 68:3322.
12. Nagabhushanam V, Solache A, Ting LM, Escaron CJ, Zhang JY, Ernst JD. Innate inhibition of adaptive immunity: Mycobacterium tuberculosisinduced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 2003; 171:4750-7.
13. Leal IS, Smedegard B, Andersen P, Appelberg R. Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine. Infect Immun 1999; 67:5747
14. Kaushal D, Schroeder BG, Tyagi S, et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A 2002; 11:8330-5.
15. Mehra S, Kaushal D. Functional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaH. J Bacteriol 2009; 191:3965-80.
16. Mehra S, Dutta NK, Mollenkopf HJ, Kaushal D. Mycobacterium tuberculosis MT2816 encodes a key stress-response regulator. J Infect Dis 2010; 202:943-53.
17. Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS One 2010; 5:e12266.
18. Mehra S, Golden NA, Stuckey K, et al. The Mycobacterium tuberculosis stress response factor SigH is required for bacterial burden as well as immunopathology in primate lungs. J Infect Dis 2012; 205:1203-13.
19. Gautam A, Dixit S, Philipp MT, et al. Interleukin-10 alters effector functions of multiple genes induced by Borrelia burgdorferi in macrophages to regulate Lyme disease inflammation. Infect Immun 2011; 79:4876-92.
20. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S. Increased expression of p-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012; 180:2490-503.
21. Madan-Lala R, Peixoto KV, Re F, Rengarajan J. Mycobacterium tuberculosis Hip1 dampens macrophage proinflammatory responses by limiting toll-like receptor 2 activation. Infect Immun 2011; 279:4828-38.
22. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693-706.
23. Nam Y, Chen C, Gregory RI, Chou JJ, Sliz P. Molecular basis for interaction of let-7 microRNAs with Lin28. Cell 2011; 147:1080-91.
24. Sun Y, Varambally S, Maher CA, et al. Targeting of microRNA-142- 3p in dendritic cells regulates endotoxin-induced mortality. Blood 2011; 117:6172-83.
25. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010; 207: 2053-63.
26. Bamezai A. Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp (Warsz) 2004; 52:255-66.
27. Seo SU, Kwon HJ, Ko HJ, et al. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 2011; 7:e1001304.
28. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
29. Colpitts SL, Stoklasek TA, Plumlee CR, Obar JJ, Guo C, Lefrancois L. Cutting edge: the role of IFN-α receptor and MyD88 signaling in induction of IL-15 expression in vivo. J Immunol 2012; 188:2483-7.
30. Fortune SM, Solache A, Jaeger A, et al. Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol 2004; 172:6272-80.
31. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-gamma-induced class II transactivator expression by a 19- kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 2003; 171:175-84.
32. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20:581-620.
33. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nature Rev Immunol 2005; 5: 675-87.
34. Manca C, et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 2005; 25:694-701.
35. Ordway D, et al. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol 2007; 179:522-31.
36. Telesca C, Angelico M, Piccolo P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect 2007; 54:e223-6.
37. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458:904-8.
38. Khor CC, Vannberg FO, Chapman SJ, et al. CISH and susceptibility to infectious diseases. N Engl J Med 2010; 362:2092-101.
39. Miah MA, Yoon CH, Kim J, Jang J, Seong YR, Bae YS. CISH is induced during DC development and regulates DC-mediated CTL activation. Eur J Immunol 2012; 42:58-68.
40. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ. A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J 2006; 20:1921-3.
41. Sabbatani S, Manfredi R, Marinacci G, Pavoni M, Cristoni L, Chiodo F. Reactivation of severe, acute pulmonary tuberculosis during treatment with pegylated interferon-alpha and ribavirin for chronic HCV hepatitis. Scand J Infect Dis 2006; 38:205-8.
42. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 2001; 167:1179-87.
43. Schierloh P, Alemán M, Yokobori N, et al. NK cell activity in tuberculosis is associated with impaired CD11a and ICAM-1 expression: a regulatory role of monocytes in NK activation. Immunology 2005; 116:541-52.
44. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10:111-22.